Bioabsorbable magnesium scaffold implantation in acute coronary syndromes: profit and medium-term results. (26th April 2021)

• Record Type: Journal Article
• Authors: Noval Morillas, I; Gutierrez Barrios, A; Gheorghe, L; Bretones Del Pino, T; Camacho, S; Calle Perez, G; Canadas Pruano, D; Vazquez Garcia, R
• Is Part Of: European heart journal. Volume 10(2021)Supplement 1
• Publication Date: 2021-04-26
• Subjects: 616.1205
• DOI: 10.1093/ehjacc/zuab020.115
• Languages: English
• ISSNs: 2048-8726

Abstract

Abstract: Funding Acknowledgements: Type of funding sources: Public hospital(s). Main funding source(s): Hospital Puerta del Mar OBJECTIVES AND METHODS: We aim to evaluate the long-term clinical and intravascular outcomes inACS patients treated with Magnesium-Based Bioresorbable Scaffold(MgBRS).Exclusion criteria:left main disease, bifurcations, ostial lesions, severe tortuosity and calcification, long lesions, high thrombus burden, haemodynamic instability, oral anticoagulants, contraindication to dual-antiplatelet therapy.Primary endpoint was the device-oriented composite end-point(DOCE):cardiac death, target vessel myocardial infarction, and target lesion revascularization(TLR).RESULTS:Between Dec2016 to Dec2018, 90patients with ACS underwent PCI with MgBRS.46%patients presented with STEMI.Mean age55.9 ± 9.9, 75.6%males and64.4%smokers.OCT was performed in 62patients.Mean scaffold length21.27 ± 7.7mm, mean diameter3.31 ± 0.24mm.15 patients required a second overlapped stent.There were 7complications:5edge dissection;1catheter-induced ostial dissection and 1case of slow-flow.Post-PCI OCT showed in-scaffold area stenosis of3.49 ± 21.29%.At 15months, diameter stenosis was31.95 ± 26.14%and restenosis was observed in 10cases(21.7%).Mean scaffold area shrinked from baseline(7.57 ± 1.77mm2)to15-month follow-up(6.13 ± 2.20mm2).The main mechanism of restenosis was scaffold collapse.DOCE was observed in 13.3%of patients.2patients with target-vessel myocardial infarction due to stent thrombosis.1case had recurrent angina at2weeks because of stent fracture and proximal edge dissection.9cases presented restenosis at different time-points.CONCLUSIONS:MgBRS is feasible in patients presenting ACS.At long-term follow-up, further development is needed to help to resolve these drawbacks